Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Abstract Background Adalimumab was effective in treating patients with nonradiographic axial spondyloarthritis (nr-axSpA) in the 12-week ABILITY-1 trial. We present long-term efficacy and safety results of adalimumab from the open-label ABILITY-1 extension, including the relationship between clinica...

Full description

Bibliographic Details
Main Authors: Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, Robert G. Lambert, Su Chen, Maja Hojnik, Jaclyn K. Anderson, Aileen L. Pangan
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Arthritis Research & Therapy
Subjects:
Anti-TNF
Axial spondyloarthritis
Adalimumab
Online Access:http://link.springer.com/article/10.1186/s13075-018-1556-5

Internet

http://link.springer.com/article/10.1186/s13075-018-1556-5

Similar Items